Brought to you by 
Genocea brings in $30mm via Series C round
12 May 2015
Executive Summary
Genocea Biosciences Inc. (developing infectious disease vaccines) has closed a $30mm Series C financing to new investors the Bill & Melinda Gates Foundation (BMGF) and CVF, and returning shareholders Polaris Venture Partners, Lux Capital, SR One, Johnson & Johnson Development Corp., Skyline Ventures, Cycad Group, Auriga Partners, MP Healthcare Ventures, and Morningside. The money will be used for ongoing development of its lead vaccine programs--Phase I/IIa GEN003 for herpes simplex virus Type 2 and preclinical GEN004 for pneumococcal infections. Funds will also support expansion of Genocea’s malaria work using its ATLAS platform in collaboration with the BMGF. The six-year-old company previously raised $23mm in its 2009 Series A and $35mm in a 2011 Series B.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genocea brings in $30mm via Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice